Stepovich M
Health Care Law Newsl. 1995 Sep;10(9):3-4.
The DOJ's latest actions suggest that MFNs in managed care contracts should be evaluated on a case-by-case basis, focusing on the actual or potential impact that the MFNs have on price competition among providers and payors in the relevant marketplace. For health care providers desiring to avoid MFNs, however, the DOJ's heightened activity in this area might furnish an appropriate reason to resist such clauses. To date, the DOJ's focus has been on the market power of payors with MFN status. However, the DOJ's reasoning applies equally to providers that wield buying power in contracting with others. Although the DOJ has yet to take up this latter issue, MFNs imposed by increasingly powerful provider organizations can expect to receive similar scrutiny from the DOJ, especially as their market influence grows.
美国司法部的最新行动表明，对管理式医疗合同中的最惠国待遇条款应逐案评估，重点关注这些条款对相关市场中供应商和付款人之间价格竞争的实际或潜在影响。然而，对于希望避免最惠国待遇条款的医疗保健供应商来说，美国司法部在这一领域加大的执法力度可能提供了一个拒绝此类条款的恰当理由。到目前为止，美国司法部的重点一直放在具有最惠国待遇地位的付款人的市场力量上。然而，美国司法部的推理同样适用于在与其他方签约时拥有采购权的供应商。尽管美国司法部尚未处理后一个问题，但越来越有影响力的供应商组织强加的最惠国待遇条款预计将受到美国司法部类似的审查，尤其是随着它们市场影响力的增强。
